ArticleInfection and drug resistance2019
Alternative eradication regimens for
Article in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Clinical relevance of the cagA and vacA s1m1 status and antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis.BMC infectious diseases · 2022Pooled it
- Computational Screening of Selected Phytochemicals Against Levofloxacin and Metronidazole-Resistant IndonesianMicroorganisms · 2026Article
- Whole genome sequence analysis ofiScience · 2025Article
- Antibiotic Resistance and Genetic Determinants ofInternational journal of molecular sciences · 2025Article
- Furazolidone susceptibility of Helicobacter pylori isolated from patients with gastroduodenal diseases in Colombia.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Review
- Exploring Alternative Treatment Choices for Multidrug-Resistant Clinical Strains ofMicroorganisms · 2023Article
- Global Antimicrobial Resistance Gene Study ofAntibiotics (Basel, Switzerland) · 2023Article
- Management of dyspepsia and Helicobacter pylori infection: the 2022 Indonesian Consensus Report.Gut pathogens · 2023Review
- Antibiotics Resistance Prevalence ofInfection and drug resistance · 2022Article
- Overview ofGut and liver · 2021Review
- Next Generation Sequencing for the Prediction of the Antibiotic Resistance inAntibiotics (Basel, Switzerland) · 2021Review
- Rifabutin for the Treatment ofPathogens (Basel, Switzerland) · 2020Review
- The Potential Benefits of Vonoprazan asPharmaceuticals (Basel, Switzerland) · 2020Review
- Noninvasive Helicobacter pylori Diagnostic Methods in Indonesia.Gut and liver · 2020Review
- The validation of the Helicobacter pylori CagA typing by immunohistochemistry: nationwide application in Indonesia.Acta histochemica · 2020Article
- BestAntibiotics (Basel, Switzerland) · 2020Review
- Characterization of a novel Helicobacter pylori East Asian-type CagA ELISA for detecting patients infected with various cagA genotypes.Medical microbiology and immunology · 2020Article
- Primary Resistance Pattern ofInfection and drug resistance · 2020Review
- Genotype profiles ofTherapeutic advances in gastroenterology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 3 countries.
Funding
Abstract
backgroundThe prevalence of
methodsWe determined the minimum inhibitory concentrations (MICs) of five alternative antibiotics for
resultAnalysis of 106 strains isolated from 1039 adult dyspeptic patients revealed that none of the strains were furazolidone-resistant. All strains were also sensitive to rifabutin and sitafloxacin. In contrast, the rates of resistance to rifaximin and garenoxacin were high (38.9% and 6.7%, respectively). The strains isolated from patients on Java Island had the highest resistance rates to garenoxacin and rifaximin. In addition, the resistance was distributed evenly among the ethnic groups, ranging between 25.0% and 69.2%. Except for rifaximin, for which the resistance rate was 38.9%, the other four antibiotics could be successfully employed to eradicate levofloxacin- and metronidazole-resistant
conclusionfurazolidone-, rifabutin-, and sitafloxacin-based therapies might be considered as alternative regimens to eradicate
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.